|
시장보고서
상품코드
2089798
세포 신호전달 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 제품 유형별, 기술별, 신호전달 경로별, 지역별 및 부문별 예측(2026-2033년)Cell Signaling Market Size, Share & Trends Analysis Report By Type (Endocrine Signaling, Paracrine Signaling), By Product (Consumables, Instruments), By Technology (Flow Cytometry, Microscopy), By Pathway, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
세포 신호전달 시장 개요
세계의 세포 신호전달 시장 규모는 2025년에 62억 달러로 추정되며, 2026년 66억 달러에서 2033년까지 115억 달러로 확대되어 2026년부터 2033년까지 연평균 성장률(CAGR)은 8.3%에 달할 것으로 예측됩니다.
2025년 기준으로 북미 시장은 세계 시장 전체의 40.0%를 차지하며 가장 큰 점유율을 기록했습니다. 전 세계적으로 암, 심혈관질환, 신경계 질환 등 만성 질환의 유병률이 증가하고 있으며, 세포 신호전달 연구의 발전이 시장 성장을 견인하고 있어, 이러한 요인들이 시장 성장의 주요 원인으로 작용하고 있습니다.
시장 역학
촉진요인 : 암 및 만성 질환의 유병률 증가
암 및 기타 만성 질환의 유병률 증가는 세포 신호전달 연구 및 관련 기술에 대한 수요를 촉진하는 주요 요인이 되고 있습니다. 세포 신호전달 경로는 증식, 분화, 세포사, 면역 반응과 같은 중요한 세포 과정을 조절합니다. 이러한 경로의 조절 이상은 암, 심혈관질환, 자가면역 질환, 신경퇴행성 질환 등의 질환과 밀접한 관련이 있습니다. 세계보건기구(WHO)의 2024년 보고서와 국제암연구소(IARC)에 따르면, 2022년에는 전 세계적으로 약 2,000만 건의 신규 암 환자와 970만 건의 암 관련 사망이 보고되었습니다. 또한, 전 세계 암 환자 수는 2050년까지 신규 환자 수가 3,500만 명을 넘어설 것으로 예측되며, 이는 2022년 수준에 비해 77% 증가한 수치에 해당합니다. 이러한 질환 발생률의 증가에 따라, 질환의 기전, 바이오마커 및 새로운 치료 표적을 규명하기 위한 첨단 세포 신호전달 연구의 필요성이 대두되고 있습니다.
또한, 만성 비감염성 질환(NCD)은 여전히 전 세계 보건 분야의 중대한 과제로 남아 있습니다. WHO의 추산에 따르면, 심혈관질환, 암, 당뇨병, 만성 호흡기질환을 포함한 비전염성 질환(NCD)은 전 세계 전체 사망의 약 74%를 차지하고 있습니다. 세포 신호전달 경로는 질환의 진행, 염증, 면역 조절, 세포 간 소통에 있어 근본적인 역할을 수행하고 있기 때문에 제약 회사와 생명공학 기업들은 신약 개발 및 정밀 의학 노력을 지원하기 위해 신호전달 경로 연구에 대한 투자를 점점 더 늘리고 있습니다. 그 결과, 만성 질환의 부담이 커짐에 따라 학술, 임상, 산업 등 각 연구 분야에서 세포 신호전달 시약, 항체, 어세이 키트, 이미징 기술 및 신호전달 경로 분석 플랫폼에 대한 수요가 급증하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 세포 신호전달 시장 : 주요 요약
제3장 세포 신호전달 시장 : 변수, 동향, 범위
제4장 세포 신호전달 시장 : 유형별 추정·동향 분석
제5장 세포 신호전달 시장 : 제품별 추정·동향 분석
제6장 세포 신호전달 시장 : 기술별 추정·동향 분석
제7장 세포 신호전달 시장 : 신호전달 경로별 추정·동향 분석
제8장 세포 신호전달 시장 : 지역별 비즈니스 분석
제9장 경쟁 구도
KSM 26.07.21Cell Signaling Market Summary
The global cell signaling market size was estimated at USD 6.2 billion in 2025 and is projected to grow from USD 6.6 billion in 2026 to USD 11.5 billion by 2033, at a CAGR of 8.3% from 2026 to 2033. The North America market held the largest share of 40.0% of the global market in 2025. The market growth driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders globally, as well as growing advancements in cell signaling research, are the prime factors driving market growth.
Market Dynamics
Driver: Increasing Prevalence of Cancer and Chronic Diseases
The rising prevalence of cancer and other chronic diseases is a major driver of demand for cell signaling research and related technologies. Cell signaling pathways regulate critical cellular processes such as proliferation, differentiation, apoptosis, and immune responses. Dysregulation of these pathways is closely associated with diseases, including cancer, cardiovascular disorders, autoimmune diseases, and neurodegenerative conditions. According to the World Health Organization (WHO) 2024 report and the International Agency for Research on Cancer (IARC), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. Moreover, the global cancer burden is projected to exceed 35 million new cases by 2050, representing a 77% increase compared to 2022 levels. These rising disease incidences are increasing the need for advanced cell signaling studies to identify disease mechanisms, biomarkers, and novel therapeutic targets.
Moreover, chronic non-communicable diseases (NCDs) continue to pose a significant global health challenge. WHO estimates that NCDs, including cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases, account for approximately 74% of all deaths worldwide. Since cell signaling pathways play a fundamental role in disease progression, inflammation, immune regulation, and cellular communication, pharmaceutical and biotechnology companies are increasingly investing in signaling pathway research to support drug discovery and precision medicine initiatives. As a result, the growing burden of chronic diseases is accelerating demand for cell signaling reagents, antibodies, assay kits, imaging technologies, and pathway analysis platforms across academic, clinical, and industrial research settings.
Global Cell Signaling Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global cell signaling market report on the basis of type, product, technology, pathways, and region.
- Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Endocrine Signaling
- Paracrine Signaling
- Autocrine Signaling
- Others
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Consumables
- Instruments
- Technology Outlook (Revenue, USD Billion, 2021 - 2033)
- Flow Cytometry
- Microscopy
- Western Blotting
- ELISA
- Others
- Pathway Outlook (Revenue, USD Billion, 2021 - 2033)
- AKT Signaling Pathway
- AMPK Signaling Pathway
- ErbB/HER Signaling Pathway
- Other Signaling Pathway
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.2. Information analysis
- 1.3. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Cell Signaling Market: Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Cell Signaling Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Increasing Prevalence of Cancer and Chronic Diseases
- 3.4.2. Growing focus on precision & targeted therapies
- 3.4.3. Advances in molecular biology & omics technologies
- 3.5. Market Restraint Analysis
- 3.5.1. High cost associated with cell signaling research
- 3.5.2. Complexity of Signaling Pathways and Data Interpretation Challenges
- 3.6. Market Opportunity Analysis
- 3.7. Market Challenges Analysis
- 3.8. Business Environment Analysis
- 3.8.1. Porter's Five Forces Analysis
- 3.8.2. PESTLE Analysis
Chapter 4. Cell Signaling Market: Type Estimates & Trend Analysis
- 4.1. Type Segment Dashboard
- 4.2. Cell Signaling Market: Type Movement Analysis
- 4.3. Cell Signaling Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Billion)
- 4.4. Endocrine Signaling
- 4.4.1. Endocrine Signaling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.5. Paracrine Signaling
- 4.5.1. Paracrine Signaling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.6. Autocrine Signaling
- 4.6.1. Autocrine Signaling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.7. Others
- 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. Cell Signaling Market: Product Estimates & Trend Analysis
- 5.1. Product Segment Dashboard
- 5.2. Cell Signaling Market: Product Movement Analysis
- 5.3. Cell Signaling Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
- 5.4. Consumables
- 5.4.1. Consumables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.5. Instruments
- 5.5.1. Instruments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. Cell Signaling Market: Technology Estimates & Trend Analysis
- 6.1. Technology Segment Dashboard
- 6.2. Cell Signaling Market: Technology Movement Analysis
- 6.3. Cell Signaling Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Billion)
- 6.4. Flow Cytometry
- 6.4.1. Flow Cytometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.5. Microscopy
- 6.5.1. Microscopy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.6. Western Blotting
- 6.6.1. Western Blotting Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.7. ELISA
- 6.7.1. ELISA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.8. Others
- 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. Cell Signaling Market: Pathway Estimates & Trend Analysis
- 7.1. Pathway Segment Dashboard
- 7.2. Cell Signaling Market: Pathway Movement Analysis
- 7.3. Cell Signaling Market Size & Trend Analysis, by Pathway, 2021 to 2033 (USD Billion)
- 7.4. AKT Signaling Pathway
- 7.4.1. AKT Signaling Pathway Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. AMPK Signaling Pathway
- 7.5.1. AMPK Signaling Pathway Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. ErbB/HER Signaling Pathway
- 7.6.1. ErbB/HER Signaling Pathway Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Other Signaling Pathways
- 7.7.1. Other Signaling Pathways Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Cell Signaling Market: Regional Business Analysis
- 8.1. Regional Market Snapshot
- 8.2. North America
- 8.2.1. North America Cell Signaling Market Estimates And Forecast, 2021 - 2033 (USD Billion)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Competitive Scenario
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. U.S. Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Competitive Scenario
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Canada Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Competitive Scenario
- 8.2.4.3. Regulatory Framework
- 8.2.4.4. Mexico Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3. Europe
- 8.3.1. Europe Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Competitive Scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. UK Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Competitive Scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Germany Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.4. Spain
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Competitive Scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. Spain Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.5. France
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Competitive Scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. France Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.6. Italy
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Competitive Scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Italy Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Competitive Scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Denmark Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Competitive Scenario
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Sweden Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Competitive Scenario
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Norway Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4. Asia Pacific
- 8.4.1. Asia-Pacific Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Japan Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. China Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. India Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.5. South Korea
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Competitive Scenario
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. South Korea Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.6. Thailand
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Competitive Scenario
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Thailand Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.4.7. Australia
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Competitive Scenario
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. Australia Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.5. Latin America
- 8.5.1. Latin America Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Brazil Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Argentina Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.6. MEA
- 8.6.1. MEA Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. South Africa Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Saudi Arabia Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. UAE Cell Signaling Market, 2021 - 2033 (USD Billion)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Kuwait Cell Signaling Market, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Market Position/Share Analysis, 2025
- 9.4. Company Profiles
- 9.4.1. Thermo Fisher Scientific, Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. QIAGEN
- 9.4.2.1. Company Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Becton, Dickinson and Company
- 9.4.3.1. Company Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Bio-Rad Laboratories Inc.
- 9.4.4.1. Company Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Bio-Techne Corporation
- 9.4.5.1. Company Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Cell Signaling Technology Inc.
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Benchmarking
- 9.4.6.3. Strategic Initiatives
- 9.4.7. Danaher
- 9.4.7.1. Company Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. Merck KGaA
- 9.4.8.1. Company Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. PerkinElmer Inc.
- 9.4.9.1. Company Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Promega Corporation
- 9.4.10.1. Company Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives
- 9.4.1. Thermo Fisher Scientific, Inc.
